-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
The study was launched in December 2016 and was carried out in 21 research centers across the country.
In addition, the study included 8 subjects who had previously received VEGFR inhibitor treatment, of which 3 patients in the apatinib group achieved partial remission (PR) and 2 patients with stable disease (SD)
In terms of safety, hypertension, hand-foot syndrome and proteinuria are the most common adverse events, which can be tolerated and controlled overall
The results of the study show that apatinib can significantly prolong the PFS and OS of RAIR-DTC patients, and the safety is tolerable
Apatinib mesylate is a Class 1 innovative drug with independent intellectual property rights developed by Hengrui Medicine for 10 years.
The study won an oral presentation opportunity at the 2020 European Society of Medical Oncology (ESMO) meeting, and was included in the official meta-reviews (Highlights), and simultaneously included in the "Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Thyroid Cancer (2021 Edition)".
